Kindbody was founded in 2018 by Cynthia Hudson, Fahimeh Sasan, Gina Bartasi, and Joanne Schneider. Kindbody has not officially endorsed a plan to participate in an IPO.

Kindbody is a network of fertility clinics that offers both virtual and in-person care. Per Forge data, Kindbody has raised a total of $306.3 million in funding over 10 rounds. Their latest funding was raised on May 1, 2023. Key investors include Google Ventures, Perceptive Advisors, Morgan Health, RRE Ventures, and Claritas Health Ventures.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Kindbody, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Kindbody

To invest in Kindbody pre-IPO

Can you invest in Kindbody pre-IPO?

Kindbody is a privately held company and is not publicly traded, therefore investing in Kindbody pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Kindbody before it goes public?

You can seek to sell your shares in Kindbody while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Kindbody shares?

To determine the value of your Kindbody shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Kindbody shares. You can also learn more about how to sell your private shares before getting started.

Is Kindbody a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Kindbody potential IPO

Will Kindbody go IPO?

Kindbody has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Kindbody’s IPO price?

The Kindbody IPO price does not exist at this time, as Kindbody is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Kindbody register for Forge Markets, today.

When was Kindbody founded?

Kindbody was founded in 2018.

What is Kindbody funding to date?

Kindbody has raised $934.23MM to date.

Who are Kindbody’s major investors?

GV
Alumni Ventures
RRE Ventures
Eldridge
Perceptive Advisors
What If Ventures
Rock Springs Capital
Monashee Investment Management
Claritas Health Ventures
Bramalea Partners

Kindbody Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/01/2023 Series D $30MM $xx.xx $1.81B Morgan Health, Perceptive Investors
Price per Share
$xx.xx
Shares Outstanding
582,329
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Morgan Health, Perceptive Investors
08/19/2022 Series C-3 $79.71MM $xx.xx $1.85B What If Ventures
Price per Share
$xx.xx
Shares Outstanding
1,547,230
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
What If Ventures
02/08/2022 Series C-2 $30MM $xx.xx $1.19B What If Ventures
Price per Share
$xx.xx
Shares Outstanding
834,725
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
What If Ventures
02/01/2022 Series C-1 $75MM $xx.xx $1.19B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,086,811
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/25/2021 Series C $61.89MM $xx.xx $670.48MM Bramalea Partners, Claritas Health Ventures, Eldridge, Gv, Monashee Investment Management, Perceptive Advisors, Rock Springs Capital, Rre Ventures
Price per Share
$xx.xx
Shares Outstanding
2,815,304
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bramalea Partners, Claritas Health Ventures, Eldridge, Gv, Monashee Investment Management, Perceptive Advisors, Rock Springs Capital, Rre Ventures
07/08/2020 Series B $32MM $xx.xx $181.18MM Claritas Health Ventures, Freemark Capital, Goodgrower, Gv, Nfp Ventures, Perceptive Advisors, Rock Springs Capital, Rre Ventures
Price per Share
$xx.xx
Shares Outstanding
5,449,590
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claritas Health Ventures, Freemark Capital, Goodgrower, Gv, Nfp Ventures, Perceptive Advisors, Rock Springs Capital, Rre Ventures
04/17/2019 Series A $22.47MM $xx.xx $127.98MM Green D Ventures, Perceptive Advisors, Rre Ventures, Trail Mix Ventures, Winklevoss Capital
Price per Share
$xx.xx
Shares Outstanding
4,273,488
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Green D Ventures, Perceptive Advisors, Rre Ventures, Trail Mix Ventures, Winklevoss Capital
01/01/2019 Series Seed $575,000.00 $xx.xx $56.23MM Chelsea Clinton, Halle Tecco, Leandra Medine, Marc Mezvinsky, Marco Demeireles, Nat Turner, Tq Ventures, Vivek Garipalli
Price per Share
$xx.xx
Shares Outstanding
287,500
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chelsea Clinton, Halle Tecco, Leandra Medine, Marc Mezvinsky, Marco Demeireles, Nat Turner, Tq Ventures, Vivek Garipalli
01/01/2019 Series Seed-2 $4.2MM $xx.xx $56.23MM Chelsea Clinton, Halle Tecco, Leandra Medine, Marc Mezvinsky, Marco Demeireles, Nat Turner, Tq Ventures, Vivek Garipalli
Price per Share
$xx.xx
Shares Outstanding
1,543,153
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chelsea Clinton, Halle Tecco, Leandra Medine, Marc Mezvinsky, Marco Demeireles, Nat Turner, Tq Ventures, Vivek Garipalli
06/30/2018 Series Founder Convertible $1.56MM $xx.xx $7.8MM Annbeth Eschbach, Gina Bartasi
Price per Share
$xx.xx
Shares Outstanding
8,500,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Annbeth Eschbach, Gina Bartasi
Updated on: Dec 3, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.